Literature DB >> 6572908

Characterization of the monoamine carrier of chromaffin granule membrane by binding of [2-3H]dihydrotetrabenazine.

D Scherman, P Jaudon, J P Henry.   

Abstract

[2-3H]Dihydrotetrabenazine (2-hydroxy-3-isobutyl-9, 10-dimethoxy-1,2,3,4,6,7-hexahydro-11b-H-benzo [a]-quinolizine), a derivative of the neuroleptic tetrabenazine, binds to the membrane of purified bovine chromaffin granules. Specific binding was characterized by Kd and Bmax values of 3.1 nM and 62 pmol/mg of membrane protein, respectively. It was reversible, with association and dissociation rate constants of 0.22 x 10(6) M-1 s-1 and 1.8 x 10(-3) s-1, respectively. Binding sites were present in extracts of medulla but not in corticoadrenal extracts; in the medulla they were restricted to chromaffin granule membranes, [2-3H]Dihydrotetrabenazine binding occurred on the catecholamine carrier of the chromaffin granule membrane because it was clearly correlated with inhibition of norepinephrine uptake. In addition, inhibitors and substrates of the uptake reaction displaced [2-3H]dihydrotetrabenazine from its binding sites, and their potency as displacers was qualitatively correlated with their IC50 or Km. These results suggest that use of [2-3H]dihydrotetrabenazine binding might be an interesting technique in the study of the vesicular monoamine carrier.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6572908      PMCID: PMC393424          DOI: 10.1073/pnas.80.2.584

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  38 in total

1.  Quantitative aspects of hormone-receptor interactions of high affinity. Effect of receptor concentration and measurement of dissociation constants of labeled and unlabeled hormones.

Authors:  K J Chang; S Jacobs; P Cuatrecasas
Journal:  Biochim Biophys Acta       Date:  1975-10-06

2.  Estimation of hormone receptor affinity by competitive displacement of labeled ligand: effect of concentration of receptor and of labeled ligand.

Authors:  S Jacobs; P Cuatrecasas
Journal:  Biochem Biophys Res Commun       Date:  1975-09-16       Impact factor: 3.575

3.  Regional distribution of [3H]imipramine binding in rat brain.

Authors:  M Palkovits; R Raisman; M Briley; S Z Langer
Journal:  Brain Res       Date:  1981-04-06       Impact factor: 3.252

4.  A simple method for the isolation of adrenal chromaffin granules on a large scale.

Authors:  A D Smith; H Winkler
Journal:  Biochem J       Date:  1967-05       Impact factor: 3.857

5.  Metabolic studies of tetrabenazine, a psychotropic drug in animals and man.

Authors:  D E Schwartz; H Bruderer; J Rieder; A Brossi
Journal:  Biochem Pharmacol       Date:  1966-05       Impact factor: 5.858

6.  The membrane of catecholamine storage vesicles of adrenal medulla. Catecholamines fluxes and ATPase activity.

Authors:  G Taugner
Journal:  Naunyn Schmiedebergs Arch Pharmakol       Date:  1971

7.  Steady-state kinetics of catecholamine transport by chromaffin-granule "ghosts".

Authors:  J H Phillips
Journal:  Biochem J       Date:  1974-11       Impact factor: 3.857

8.  Dopamine-beta-hydroxylase: a tetrameric glycoprotein.

Authors:  E F Wallace; M J Krantz; W Lovenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1973-08       Impact factor: 11.205

9.  Transport of catecholamines by resealed chromaffin-grnaule "ghosts".

Authors:  J H Phillips
Journal:  Biochem J       Date:  1974-11       Impact factor: 3.857

10.  Solubilization and reconstitution of the adenosine 5'-triphosphate dependent noradrenaline uptake system of bovine chromaffin granule membrane.

Authors:  M F Isambert; J P Henry
Journal:  Biochimie       Date:  1981-03       Impact factor: 4.079

View more
  34 in total

1.  Tetrabenazine: for chorea associated with Huntington's disease.

Authors:  Lesley J Scott
Journal:  CNS Drugs       Date:  2011-12-01       Impact factor: 5.749

Review 2.  Minireview: Dopaminergic regulation of insulin secretion from the pancreatic islet.

Authors:  Alessandro Ustione; David W Piston; Paul E Harris
Journal:  Mol Endocrinol       Date:  2013-06-06

3.  Association of the GTP-binding protein Rab3A with bovine adrenal chromaffin granules.

Authors:  F Darchen; A Zahraoui; F Hammel; M P Monteils; A Tavitian; D Scherman
Journal:  Proc Natl Acad Sci U S A       Date:  1990-08       Impact factor: 11.205

Review 4.  Proton-dependent multidrug efflux systems.

Authors:  I T Paulsen; M H Brown; R A Skurray
Journal:  Microbiol Rev       Date:  1996-12

5.  Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators.

Authors:  Samuel Frank
Journal:  BMC Neurol       Date:  2009-12-18       Impact factor: 2.474

6.  Emulating proton-induced conformational changes in the vesicular monoamine transporter VMAT2 by mutagenesis.

Authors:  Dana Yaffe; Ariela Vergara-Jaque; Lucy R Forrest; Shimon Schuldiner
Journal:  Proc Natl Acad Sci U S A       Date:  2016-11-07       Impact factor: 11.205

Review 7.  Design, synthesis and interaction at the vesicular monoamine transporter-2 of lobeline analogs: potential pharmacotherapies for the treatment of psychostimulant abuse.

Authors:  Peter A Crooks; Guangrong Zheng; Ashish P Vartak; John P Culver; Fang Zheng; David B Horton; Linda P Dwoskin
Journal:  Curr Top Med Chem       Date:  2011       Impact factor: 3.295

8.  Comparison of the subregional distributions of the monoamine vesicular transporter and dopamine uptake complex in the rat striatum and changes during aging.

Authors:  I Leroux-Nicollet; J Costentin
Journal:  J Neural Transm Gen Sect       Date:  1994

9.  Directed evolution reveals hidden properties of VMAT, a neurotransmitter transporter.

Authors:  Yael Gros; Shimon Schuldiner
Journal:  J Biol Chem       Date:  2009-12-10       Impact factor: 5.157

10.  Human methamphetamine pharmacokinetics simulated in the rat: behavioral and neurochemical effects of a 72-h binge.

Authors:  Ronald Kuczenski; David S Segal; William P Melega; Goran Lacan; Stanley J McCunney
Journal:  Neuropsychopharmacology       Date:  2009-07-01       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.